Literature DB >> 3988614

Intraocular lenses and anticoagulation and antiplatelet therapy.

L S Stone, O R Kline, C Sklar.   

Abstract

Questionnaires were sent to 200 members of the American Intra-Ocular Implant Society to assess the preoperative, intraoperative, and postoperative management trends with intraocular lens implant patients on warfarin sodium and aspirin therapy. Responses were received from 135 members. A sizable majority of practitioners (75%) withhold warfarin sodium both prior to and following surgery. In many cases, the medicine is withheld for longer than is necessary, increasing the risk of medical complications. Respondents slightly favored (53%) discontinuing aspirin, which is perceived to be less harmful than warfarin sodium, preoperatively. Although management decisions must be individualized, according to both the surgeon's technique and the particular patient, certain general guidelines are applicable.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3988614     DOI: 10.1016/s0146-2776(85)80013-6

Source DB:  PubMed          Journal:  J Am Intraocul Implant Soc        ISSN: 0146-2776


  5 in total

1.  Aspirin and warfarin therapy in oculoplastic surgery.

Authors:  B Parkin; R Manners
Journal:  Br J Ophthalmol       Date:  2000-12       Impact factor: 4.638

2.  Anticoagulant therapy and cataract surgery.

Authors:  A C Moll; G van Rij; T L van der Loos
Journal:  Doc Ophthalmol       Date:  1989-08       Impact factor: 2.379

Review 3.  Regional anaesthesia for intraocular surgery.

Authors:  D H Wong
Journal:  Can J Anaesth       Date:  1993-07       Impact factor: 5.063

4.  Warfarin and cataract extraction.

Authors:  G A Robinson; A Nylander
Journal:  Br J Ophthalmol       Date:  1989-09       Impact factor: 4.638

5.  Randomised controlled trial on vitreoretinal surgery with and without oral anticoagulants: surgical complications, visual results and perioperative thromboembolic events.

Authors:  Jose Andonegui; Ferran Capdevila; Alicia Zubicoa; Berta Ibáñez
Journal:  Trials       Date:  2019-12-04       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.